|
1
|
Moch H: An overview of renal cell cancer:
Pathology and genetics. Semin Cancer Biol. 23:3–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pecuchet N, Fournier LS and Oudard S: New
insights into the management of renal cell cancer. Oncology.
84:22–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Flanigan RC, Campbell SC, Clark JI and
Picken MM and Picken MM: Metastatic renal cell carcinoma. Curr
Treat Options Oncol. 4:385–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yao X, Qi L, Chen X, Du J, Zhang Z and Liu
S: Expression of CX3CR1 associates with cellular migration,
metastasis, and prognosis in human clear cell renal cell carcinoma?
Urol Oncol. 32:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Escudier B, Albiges L and Sonpavde G:
Optimal management of metastatic renal cell carcinoma: Current
status. Drugs. 73:427–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun M, Shariat SF, Trinh QD, Meskawi M,
Bianchi M, Hansen J, Abdollah F, Perrotte P and Karakiewicz PI: An
evidence-based guide to the selection of sequential therapies in
metastatic renal cell carcinoma. Ther Adv Urol. 5:121–128. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Washio M, Mori M, Mikami K, Miki T,
Watanabe Y, Nakao M, Kubo T, Suzuki K, Ozasa K, Wakai K and
Tamakoshi A: Risk factors for renal cell carcinoma in a Japanese
population. Asian Pac J Cancer Prev. 15:9065–9070. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Syrios J, Kechagias G and Tsavaris N:
Treatment of patients with metastatic renal cell carcinoma
undergoing hemodialysis: Case report of two patients and short
literature review. BMC Nephrol. 14:842013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ljungberg B: The role of metastasectomy in
renal cell carcinoma in the era of targeted therapy. Curr Urol Rep.
14:19–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin JC, Liao SK, Lee EH, Hung MS, Sayion
Y, Chen HC, Kang CC, Huang LS and Cherng JM: Molecular events
associated with epithelial to mesenchymal transition of
nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus
genome. J Biomed Sci. 16:1052009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Palena C, Hamilton DH and Fernando RI:
Influence of IL-8 on the epithelial-mesenchymal transition and the
tumor microenvironment. Future Oncol. 8:713–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bates RC, DeLeo MJ III and Mercurio AM:
The epithelial-mesenchymal transition of colon carcinoma involves
expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res.
299:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Esteban MA, Bao X, Zhuang Q, Zhou T, Qin B
and Pei D: The mesenchymal-to-epithelial transition in somatic cell
reprogramming. Curr Opin Genet Dev. 22:423–428. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mikami S, Oya M, Mizuno R, Kosaka T,
Katsube K and Okada Y: Invasion and metastasis of renal cell
carcinoma. Med Mol Morphol. 47:63–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Todorović-Raković N and Milovanović J:
Interleukin-8 in breast cancer progression. J Interferon Cytokine
Res. 33:563–570. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prud'homme GJ: Cancer stem cells and novel
targets for antitumor strategies. Curr Pharm Des. 18:2838–2849.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang D, Ding Y, Zhou M, Rini BI, Petillo
D, Qian CN, Kahnoski R, Futreal PA, Furge KA and Teh BT:
Interleukin-8 mediates resistance to antiangiogenic agent
sunitinibin renal cell carcinoma. Cancer Res. 70:1063–1071. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Radisavljevic Z: AKT as locus of cancer
angiogenic robustness and fragility. J Cell Physiol. 228:21–24.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hasan MK, Nafady A, Takatori A, Kishida S,
Ohira M, Suenaga Y, Hossain S, Akter J, Ogura A, Nakamura Y, et al:
ALK is regulates a MYCN target gene and cell migration and invasion
in neuroblastoma. Sci Rep. 3:34502013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai Z, Tai Y, Li W, Zhen C, Gu W, Jian Z,
Wang Q, Lin JE, Zhao Q, Gong W, et al: Gankyrin activates IL-8 to
promote hepatic metastasis of colorectal cancer. Cancer Res.
73:4548–4558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Umekawa K, Kimura T, Kudoh S, Suzumura T,
Oka T, Nagata M, Mitsuoka S, Matsuura K, Nakai T, Yoshimura N, et
al: Plasma RANTES, IL-10 and IL-8 levels in non-small-cell lung
cancer patients treated with EGFR-TKIs. BMC Res Notes. 6:1392013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai
H, Li P, Cao Q, Ju X, Meng X, et al: miR-154 inhibits EMT by
targeting HMGA2 in prostate cancer cells. Mol Cell Biochem.
379:69–75. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gheldof A and Berx G: Cadherins and
epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci.
116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simic P, Williams EO, Bell EL, Gong JJ,
Bonkowski M and Guarente L: SIRT1 suppresses the
epithelial-to-mesenchymal transition in cancer metastasis and organ
fibrosis. Cell Rep. 3:1175–1186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Carpenter RL and Jiang BH: Roles of EGFR,
PI3K, AKT, and mTOR in heavy metal-induced cancer. Curr Cancer Drug
Targets. 13:252–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong X and Pelling JC: Targeting the
PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer
Agents Med Chem. 13:971–978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dobbin Zc and Landen CN: The Importance of
the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int
J Mol Sci. 14:8213–8227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu H, Bhaijee F, Ishaq N, Pepper DJ,
Backus K, Brown AS, Zhou X and Miele L: Correlation of Notch1, pAKT
and nuclear NF-κB expression in triple negative breast cancer. Am J
Cancer Res. 3:230–239. 2013.PubMed/NCBI
|
|
29
|
Larkin J, Swanton C and Pickering L:
Optimizing treatment of metastatic renal cell carcinoma by changing
mechanism of action. Expert Rev Anticancer Ther. 11:639–649. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li F, Yin X, Luo X, Li HY, Su X, Wang XY,
Chen L, Zheng K and Ren GS: Livin promotes progression of breast
cancer through induction of epithelial-mesenchymal transition and
activation of AKT signaling. Cell Signal. 25:1413–1422. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gamelin E, Mertins SD, Regis JT, Mickley
L, Abati A, Worrell RA, Linehan WM and Bates SE: Intrinsic drug
resistance in primary and metastatic renal cell carcinoma. J Urol.
162:217–224. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Soria G, Ofri-Shahak M, Haas I,
Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P,
Meshel T, Shabtai E, Gutman M and Ben-Baruch A: Inflammatory
mediators in breast cancer: Coordinated expression of TNFα &
IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal
transition. BMC Cancer. 11:1302011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu
YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis
factor-alpha promotes progression and epithelial-mesenchymal
transition in renal cell carcinoma cells. Cancer Sci. 99:905–913.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aggarwal BB, Shishodia S, Sandur SK,
Pandey MK and Sethi G: Inflammation and cancer: How hot is the
link? Biochem Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shen XH, Xu SJ, Jin CY, Ding F, Zhou YC
and Fu GS: Interleukin-8 prevents oxidative stress-induced human
endothelial cell senescence via telomerase activation. Int
Immunopharmacol. 16:261–267. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fernando RI, Castillo MD, Litzinger M,
Hamilton DH and Palena C: IL-8 signaling plays a critical role in
the epithelial-mesenchymal transition of human carcinoma cells.
Cancer Res. 71:5296–5306. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mathias RA, Chen YS, Wang B, Ji H, Kapp
EA, Moritz RL, Zhu HJ and Simpson RJ: Extracellular remodelling
during oncogenic Ras-induced epithelial-mesenchymal transition
facilitates MDCK cell migration. J Proteome Res. 9:1007–1019. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arima Y, Hayashi N, Hayashi H, Sasaki M,
Kai K, Sugihara E, Abe E, Yoshida A, Mikami S, Nakamura S and Saya
H: Loss of p16 expression is associated with the stem cell
characteristics of surface markers and therapeutic resistance in
estrogen receptor negative breast cancer. Int J Cancer.
130:2568–2579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Juvekar A and Wulf GM: Closing escape
routes: Inhibition of IL-8 signaling enhances the anti-tumor
efficacy of PI3K inhibitors. Breast Cancer Res. 15:3082013.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kohn AD, Takeuchi F and Roth RA: Akt, a
pleckstrin homology domain containing kinase, is activated
primarily by phosphorylation. J Biol Chem. 271:21920–21926. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Okui G, Tobiume K, Rizqiawan A, Yamamoto
K, Shigeishi H, Ono S, Higashikawa K and Kamata N: AKT primes
snail-induced EMT concomitantly with the collective migration of
squamous cells. J Cell Biochem. 114:2039–2049. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grund EM, Kagan D, Tran CA, Zeitvogel A,
Starzinski-Powitz A, Nataraja S and Palmer SS: Tumor necrosis
factor-alpha regulates inflammatory and mesenchymal responses via
mitogen-activated protein kinase kinase, p38, and nuclear factor
kappaB in human endometriotic epithelial cells. Mol Pharmacol.
73:1394–1404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li G, Zhang Y, Qian Y, Zhang H, Guo S,
Sunagawa M, Hisamitsu T and Liu Y: Interleukin-17A promotes
rheumatoid arthritis synoviocytes migration and invasion under
hypoxia by increasing MMP2 and MMP9 expression through NF-κB/HIF-1α
pathway. Mol Immunol. 53:227–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kiefel H, Bondong S, Pfeifer M, Schirmer
U, Erbe-Hoffmann N, Schäfer H, Sebens S and Altevogt P:
EMT-associated up-regulation of L1CAM provides insights into
L1CAM-mediated integrin signalling and NF-κB activation.
Carcinogenesis. 33:1919–1929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kang YH, Ji NY, Han SR, Lee CI, Kim JW,
Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW, et al: ESM-1 regulates
cell growth and metastatic process through activation of NF-κB in
colorectal cancer. Cell Signal. 24:1940–1949. 2012. View Article : Google Scholar : PubMed/NCBI
|
